SCHEMBL4740222

SCHEMBL4740222

Nc1onc2cccc(-c3ccc(NC(=O)Nc4ccc(F)c(Cl)c4)cc3)c12

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDR P35968 17/20 0.72
▸ FLT3 P36888 13/20 0.72
▸ KIT P10721 12/20 0.72
▸ MET P08581 1/20 0.61
▸ PDGFRB P09619 4/20 0.54
▸ CSF1R P07333 2/20 0.53
▸ FLT1 P17948 2/20 0.53
▸ AURKA O14965 1/20 0.53
▸ ROCK2 O75116 1/20 0.53
▸ RPS6KA5 O75582 1/20 0.53
▸ NTRK1 P04629 1/20 0.53
▸ LCK P06239 1/20 0.53
▸ LYN P07948 1/20 0.53
▸ RET P07949 1/20 0.53
▸ FGFR1 P11362 1/20 0.53
▸ FER P16591 1/20 0.53
▸ RPS6KB1 P23443 1/20 0.53
▸ FLT4 P35916 1/20 0.53
▸ FRK P42685 1/20 0.53
▸ BLK P51451 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1383493 0.89 KDR (0.72) KDRFLT3KITPDGFRBCSF1R
SCHEMBL1380731 0.88 KDR (0.72) KDRFLT3KITPDGFRBCSF1R
SCHEMBL4736063 0.86 KDR (0.70) KDRFLT3KITPDGFRBCSF1R
SCHEMBL5249583 0.86 KDR (0.73) KDRFLT3KITPDGFRBCSF1R
SCHEMBL1382612 0.86 KDR (0.68) KDRFLT3KITMETPDGFRB
SCHEMBL4740182 0.86 KDR (0.72) KDRFLT3KITPDGFRBCSF1R
SCHEMBL1383067 0.85 KDR (0.73) KDRFLT3KITMETPDGFRB
SCHEMBL4735263 0.85 KDR (0.70) KDRFLT3KITMETPDGFRB
SCHEMBL423450 0.84 KIT (1.00) KDRFLT3KITMETCSF1R
SCHEMBL1383101 0.84 KDR (0.67) KDRFLT3KITMETPDGFRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008080110-A1 METHODS FOR TREATING MACULAR EDEMA AND PATHOLOGIC OCULAR ANGIOGENESIS USING A NEUROPROTECTIVE AGENT AND A RECEPTOR TYROSINE KINASE INHIBITOR ALCON, INC. (CH) 2008-07-03 — — WO claimed
EP-1850839-A2 METHODS FOR TREATING OCULAR ANGIOGENESIS, RETINAL EDEMA, RETINAL ISCHEMIA, AND DIABETIC RETINOPATHY USING SELECTIVE RTK INHIBITORS ALCON INC. (CH) 2007-11-07 — — EP claimed
WO-2006091801-A2 METHODS FOR TREATING OCULAR ANGIOGENESIS, RETINAL EDEMA, RETINAL ISCHEMIA, AND DIABETIC RETINOPATHY USING SELECTIVE RTK INHIBITORS ALCON, INC. (CH) 2006-08-31 — — WO claimed
WO-2008080110-A1 METHODS FOR TREATING MACULAR EDEMA AND PATHOLOGIC OCULAR ANGIOGENESIS USING A NEUROPROTECTIVE AGENT AND A RECEPTOR TYROSINE KINASE INHIBITOR ALCON, INC. (CH) 2008-07-03 — — WO disclosed
Send feedback